Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor DayBusiness Wire • 11/13/25
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal DiseaseAccesswire • 11/05/25
Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/22/25
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + LombBenzinga • 10/20/25
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TVAccesswire • 09/30/25
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to DentistryAccesswire • 09/29/25
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease PortfolioAccesswire • 09/11/25
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical TrialBusiness Wire • 09/11/25
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens WearersBusiness Wire • 09/09/25
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical SystemAccesswire • 09/05/25
Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/29/25
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025Accesswire • 08/26/25
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and SaskatchewanAccesswire • 08/21/25
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board ChangesAccesswire • 08/15/25